Giudice, Elena
 Distribuzione geografica
Continente #
NA - Nord America 159
EU - Europa 140
AS - Asia 129
SA - Sud America 15
AF - Africa 3
Totale 446
Nazione #
US - Stati Uniti d'America 156
SG - Singapore 55
IT - Italia 37
IN - India 25
CN - Cina 21
DE - Germania 17
IE - Irlanda 17
FI - Finlandia 16
BR - Brasile 14
ID - Indonesia 13
FR - Francia 11
SE - Svezia 10
AT - Austria 6
GB - Regno Unito 6
RU - Federazione Russa 6
NL - Olanda 5
KR - Corea 4
ES - Italia 3
AW - Aruba 2
CZ - Repubblica Ceca 2
IL - Israele 2
JP - Giappone 2
AR - Argentina 1
BE - Belgio 1
BG - Bulgaria 1
CA - Canada 1
CI - Costa d'Avorio 1
GA - Gabon 1
GE - Georgia 1
HK - Hong Kong 1
HU - Ungheria 1
IQ - Iraq 1
IR - Iran 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
VN - Vietnam 1
Totale 446
Città #
Singapore 44
Ashburn 33
Chandler 27
Hyderabad 24
Dublin 17
Helsinki 15
Jakarta 13
Rome 11
New York 8
San Mateo 6
Washington 6
Düsseldorf 5
Frankfurt am Main 5
Moscow 5
Beijing 4
Lauterbourg 4
Los Angeles 4
Milan 4
Munich 4
New Haven 4
Vienna 4
Amsterdam 3
Asti 3
Boston 3
Busto Arsizio 3
Jeju City 3
Marseille 3
Portsmouth 3
Princeton 3
Bari 2
Falkenstein 2
Guidonia Montecelio 2
Nave 2
Newark 2
Olomouc 2
Oranjestad 2
Osimo 2
Pamplona 2
Paris 2
Tel Aviv 2
Tokyo 2
Abidjan 1
Almaty 1
Andover 1
Antwerp 1
Araucária 1
As Samawah 1
Boa Vista 1
Brussels 1
Budapest 1
Buenos Aires 1
Cambridge 1
Campos dos Goytacazes 1
Canarana 1
Chelyabinsk 1
Colombo 1
Council Bluffs 1
Edgerton 1
Fazenda Rio Grande 1
Guarulhos 1
Hanoi 1
Hong Kong 1
Itapaci 1
Itu 1
João Pessoa 1
Jundiaí 1
Kansas City 1
Lappeenranta 1
Leawood 1
Leipzig 1
Leopoldina 1
Libreville 1
Madrid 1
Monteiro 1
Mountain View 1
Norwalk 1
Puyang Chengguanzhen 1
Redwood City 1
Santa Clara 1
Seattle 1
Shanghai 1
Sofia 1
Stockholm 1
Suyeong-gu 1
São Paulo 1
Tappahannock 1
Tbilisi 1
Toronto 1
Uberlândia 1
York 1
Zanjan 1
Totale 345
Nome #
Pembrolizumab for advanced cervical cancer: safety and efficacy 49
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 48
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 47
PARP Inhibitors Resistance: Mechanisms and Perspectives 43
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 40
Recent progress in the use of pharmacotherapy for endometrial cancer 37
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 36
Advanced and recurrent endometrial cancer: State of the art and future perspectives 36
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 31
Management of stage III and IVa uterine cancer 28
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 24
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 22
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 21
Totale 462
Categoria #
all - tutte 3.412
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.412


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 1 0 0 0 1 0
2021/202225 0 0 0 5 0 0 1 7 2 1 2 7
2022/202384 6 9 2 9 2 8 4 3 6 9 19 7
2023/2024157 4 25 17 16 4 21 19 3 5 5 18 20
2024/2025194 8 4 31 6 20 20 14 6 30 54 1 0
Totale 462